Replies to post #48852 on Biotech Values

[dewophile]

thanks
from an investment perspective data on depo's formulation of gabapentin are due out soon. It strikes me as a low risk event given the proven efficacy for neurontin in post-herpetic neuralgia. I'm just trying to figure out if the street will care much based on the commercial potential of the product